The pilot study of vosaroxin and cytarabine for the treatment of older adults with previously untreated acute myeloid leukemia (AML) was terminated due to safety concerns, with only 2 patients enrolled. The limited patient population and the early termination of the trial suggest significant challenges in the development of this combination therapy. The market for AML treatments is competitive, with established therapies and emerging options. The failure to demonstrate safety and efficacy in this trial may hinder future investment and development of vosaroxin, particularly in the context of older patients who are often underrepresented in clinical trials. Companies focusing on AML therapies will need to consider alternative strategies or combinations to address this patient demographic effectively.